Analysis of the Response of Prostate Cancer to Ultra-Hypofractionated High-Dose-Rate Brachytherapy: The Role of Hypoxia and Reoxygenation.

Background/

Objectives

Clinical studies of prostate cancer treated with radically hypofractionated high-dose-rate brachytherapy (HDR-BT) have reported a significant loss of tumor control that contradicts the standard linear-quadratic (LQ) and low-α/β-ratio paradigm for prostate cancer. In a previous study by our group, we showed that the linear-quadratic-linear (LQL) model could describe this response, but the underlying biological drivers remained unclear. In this follow-up study, we further investigate whether the interplay between hypoxia and reoxygenation kinetics can explain the poor response to extreme hypofractionation.

Methods

We analyzed a large dataset of 3239 patients (44 schedules) using a three-compartment reoxygenation model (the MSK model) that simulates the dynamics of oxic, intermediate, and hypoxic cell populations.

Results

The results show that the MSK model achieves an excellent fit to the clinical data (p>0.99) while maintaining a biologically plausible low α/β ratio (≤8 Gy). The reoxygenation model provided a performance comparable to the LQL model for low-risk prostate cancer and slightly inferior for intermediate-risk.

Conclusions

This suggests that the observed reduction in tumor control may not necessarily be a failure of the LQ formalism but, rather, a consequence of oxygen dynamics associated with ultra-hypofractionated schedules. Nonetheless, neither this nor our previous work can provide insight into the driving mechanism and should only be interpreted as showing that both hypotheses are compatible with the clinical data.